Chronic hepatitis B virus infection leads to about 1 million deaths per year, making it one of the top ten causes of death worldwide. An improved understanding of defective antiviral responses in chronic hepatitis B virus infection could allow specific immunotherapeutic interventions, enhancing the immune response to hepatitis B virus.